 NEW YORK, Oct. 27, 2020 GLOBE NEWSWIRE -- Prevail Therapeutics Inc. Nasdaq: PRVL, a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation for the Companys experimental gene therapy program, PR001, for the treatment of neuronopathic Gaucher disease nGD. The Company expects to initiate enrollment of the PROVIDE Phase 12 clinical trial of PR001 for Type 2 neuronopathic Gaucher disease patients in the second half of 2020. 